ADMA
ADMA Biologics, Inc. · Healthcare
Insiders bought $468K of ADMA Biologics, Inc. in the last 12 months
2 insiders bought on 4 days.
ADMA over the last year
Largest buyers, last 12 months
ADMA after insider buys
3 months after each buy, from the first price a copier could get.
8 buys since 2016 with 3 months of prices.
Every filing
52 insider filings since 2016, newest first
Jerrold B Grossman · Director
Jerrold B Grossman · Director
Jerrold B Grossman · Director
Adam S Grossman · President and CEO
Kaitlin M. Kestenberg-Messina · COO, SVP, Compliance
Steve Elms · Director
Adam S Grossman · President and CEO
Adam S Grossman · President and CEO
Adam S Grossman · President and CEO
Brad L. Tade · CFO and Treasurer
Adam S Grossman · President and CEO
Lawrence P. Guiheen · Director
Kaitlin M. Kestenberg-Messina · COO, SVP, Compliance
Jerrold B Grossman · Director
Adam S Grossman · President and CEO
Young Kwon · Director
Adam S Grossman · Pres,CEO,, Interim CFO
Steve Elms · Director
Steve Elms · Director
Young Kwon · Director
Bryant Fong · Director
Adam S Grossman · President and CEO
Adam S Grossman · President and CEO
Brian Lenz · EVP and CFO
Adam S Grossman · President and CEO
Young Kwon · Director
Jerrold B Grossman · Director
Brian Lenz · EVP and CFO
Adam S Grossman · President and CEO
Perceptive Advisors LLC · 10% owner
Perceptive Advisors LLC · 10% owner
Perceptive Advisors LLC · 10% owner
Perceptive Advisors LLC · 10% owner
Jerrold B Grossman · Director
Perceptive Advisors LLC · 10% owner
Perceptive Advisors LLC · 10% owner
Lawrence P. Guiheen · Director
Jerrold B Grossman · Director
Adam S Grossman · President and CEO
Biotest Divestiture Trust · 10% owner
Perceptive Advisors LLC · 10% owner
Jerrold B Grossman · Director
Lawrence P. Guiheen · Director
Adam S Grossman · President and CEO
Jerrold B Grossman · Director
Adam S Grossman · President and CEO
Lawrence P. Guiheen · Director
Biotest AG · Director and 10% owner
Eric I Richman · Director
Adam S Grossman · President and CEO
About ADMA Biologics, Inc.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.